Moon Surgical Receives FDA Clearance for Maestro™ Connectivity and Predetermined Change Control Plan for AI-Powered ScoPilot®

With this clearance, Maestro Systems can now have active Wi-Fi and 5G connectivity, enabling seamless data exchange with Maestro Insights—Moon’s cloud-based platform that gives surgical teams and administrators access to actionable insights from procedural data.
MiRus Siegel™ TAVR US Early Feasibility Study (EFS) 30 Day Results Presented at NY Valves Meeting
At 30 days, there were no deaths, strokes or re-hospitalizations. No patients had vascular complications, PVL (> moderate) or required a permanent pacemaker. Core lab echocardiographic data demonstrated a mean gradient of 6.3 mmHg, and valve area of 2.8 cm2 .
The Future of Home Healthcare: Bridging the Gap Between Hospital and Home
The future of home healthcare is transforming the way individuals think about, receive, and experience medical care. Home healthcare bridges the gap between traditional hospital facilities and contemporary, patient-centered alternatives.
Why Choose Hands-On, Real-Patient Training for Your Dental Implant Career?

Hands-on, real-patient training bridges that gap, providing invaluable experience that builds both confidence and capability. For dentists serious about growing a successful implant practice, this approach is not just beneficial—it’s essential.
A Summer Reboot for Your Gut Health and Achy Joints | By Dr Marty Jaramillo, Medical Advisor to AposHealth

You may be surprised to learn the role that your gut health plays in the health of your joints. Remember, your gut is the home to thousands of microorganisms that play a role in your digestion, immunity, and overall health. When your gut microbiome is unbalanced, it can cause inflammation throughout your body, including in your joints, which is why eating healthy is vital for anyone living with chronic joint pain.
The Relevance of Income Protection Insurance to the Medical Industry
When considering the weighty challenges, demands, and risks associated with healthcare professions, it’s easy to conclude that income protection insurance is a prudent, responsible means to promote improved mental health and fiscal responsibility.
LICORbio Expands Portfolio with Strategic Acquisition of SERVA Electrophoresis
The acquisition significantly broadens LICORbio’s electrophoresis offerings, allowing the company to deliver an end-to-end workflow with an expanded suite of products tailored to the evolving needs of proteomics researchers worldwide.
Field Medical Closes Oversubscribed $35 Million Series B to Advance Development of FieldForce™ Pulsed Field Ablation Platform

The Series B financing will support the initiation of the company’s pivotal VERITAS trial, advance the FieldForce Ablation System development, and further expand Field Medical’s clinical and regulatory capabilities.
CorNav Corporation Collaborates with Mayo Clinic on New Ventricular Tachycardia Treatment
The goal of this new agreement is to help CorNav more effectively develop the means to address this important unmet need and improve the epicardial treatment of VT that afflicts millions of people in the United States and around the world, explains James Fonger, M.D., founder and CEO.
Dr. Udo Hoffmann Named Chief Medical, Scientific and AI Officer; Amit Relia Promoted to Chief Regulatory Officer at Cleerly
Strategic promotions strengthen Cleerly’s executive team as company accelerates growth.
Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business
SpringWorks immediately adds revenue and accelerates mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business sector. Acquisition marks the formation of a rare tumor business for Merck KGaA, Darmstadt, Germany including SpringWorks’ portfolio and pimicotinib. SpringWorks’ rare tumor portfolio includes Ogsiveo, a first-in-disease systemic therapy for adults with desmoid tumors and Gomekli a first and only approved therapy for adults and children with NF1-PN.
Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial
SENS-501, including the surgical delivery of the gene therapy, shows a good safety profile in all patients treated so far. 3 month results from a SENS-501 treated toddler in the first cohort demonstrate early promising hearing improvement. The second cohort assessing a higher dose of SENS-501 is ongoing and recruitment is close to being completed.